US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

ANNX

Annexon (ANNX)

Annexon Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ANNX

1 2 3 4 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
13/01/2025	07:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANNX	Annexon Inc
08/01/2025	16:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANNX	Annexon Inc
19/12/2024	15:33	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ANNX	Annexon Inc
14/11/2024	17:46	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ANNX	Annexon Inc
14/11/2024	15:10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ANNX	Annexon Inc
08/11/2024	13:17	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:ANNX	Annexon Inc
15/10/2024	13:03	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ANNX	Annexon Inc
15/08/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ANNX	Annexon Inc
12/08/2024	15:59	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ANNX	Annexon Inc
06/06/2024	20:57	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ANNX	Annexon Inc
16/04/2024	08:00	GlobeNewswire Inc.	Turnstone Biologics Appoints William Waddill to its Board of Directors	NASDAQ:ANNX	Annexon Inc
14/02/2024	19:46	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ANNX	Annexon Inc
12/02/2024	15:24	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ANNX	Annexon Inc
23/01/2024	16:00	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:ANNX	Annexon Inc
07/01/2024	19:00	GlobeNewswire Inc.	Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases	NASDAQ:ANNX	Annexon Inc
27/12/2023	05:30	GlobeNewswire Inc.	Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:ANNX	Annexon Inc
22/12/2023	16:28	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ANNX	Annexon Inc
20/12/2023	16:27	GlobeNewswire Inc.	Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock	NASDAQ:ANNX	Annexon Inc
20/12/2023	16:24	Edgar (US Regulatory)	Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses	NASDAQ:ANNX	Annexon Inc
20/12/2023	16:10	GlobeNewswire Inc.	Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint	NASDAQ:ANNX	Annexon Inc
20/12/2023	16:08	GlobeNewswire Inc.	Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway	NASDAQ:ANNX	Annexon Inc
18/12/2023	15:01	GlobeNewswire Inc.	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ANNX	Annexon Inc
22/11/2023	15:01	GlobeNewswire Inc.	Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference	NASDAQ:ANNX	Annexon Inc
13/11/2023	05:30	GlobeNewswire Inc.	Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results	NASDAQ:ANNX	Annexon Inc
09/11/2023	05:30	GlobeNewswire Inc.	Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference	NASDAQ:ANNX	Annexon Inc
24/10/2023	05:30	GlobeNewswire Inc.	Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy	NASDAQ:ANNX	Annexon Inc
10/10/2023	05:30	GlobeNewswire Inc.	Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)	NASDAQ:ANNX	Annexon Inc
19/09/2023	05:30	GlobeNewswire Inc.	Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference	NASDAQ:ANNX	Annexon Inc
18/09/2023	15:01	GlobeNewswire Inc.	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ANNX	Annexon Inc
07/08/2023	05:30	GlobeNewswire Inc.	Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results	NASDAQ:ANNX	Annexon Inc

Showing the most relevant articles for your search:NASDAQ:ANNX

1 2 3 4 Próxima >

Deutsche Telekom (QX)

Health Care Select Sector

Invesco QQQ Trust Series 1

Financial Select Sector

JP Morgan Chase

BNP Paribas (QX)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones